NQO2 (P16083) — Function-Assignment Hypothesis Review
Hypothesis: NQO2 has NAD(P)H dehydrogenase (quinone) activity (GO:0003955).
Focus: function_assignment · existing IBA annotation (GO_REF:0000033) · slug function-hypothesis-go-0003955
Gene: human NQO2 / UniProt P16083
Executive Judgment
Verdict: Over-annotated → recommend REMOVAL of the IBA GO:0003955 (activity real, but this specific term is substrate-incorrect and redundant).
NQO2 is unequivocally a flavin-dependent, two-electron quinone reductase, so the quinone-reductase concept is correct. But the specific term GO:0003955 "NAD(P)H dehydrogenase (quinone) activity" (reaction: NAD(P)H + quinone → NAD(P)⁺ + quinol) makes a cofactor/substrate claim that NQO2 does not satisfy. The definitive enzymology (Wu et al., 1997, PMID:9367528) shows NQO2 "uses dihydronicotinamide riboside (NRH) rather than NAD(P)H as an electron donor." UniProt (P16083) codifies this as EC 1.10.5.1; the NAD(P)H reaction (EC 1.6.5.2) belongs to the paralog NQO1 (P15559).
Two ontology facts (verified via QuickGO this iteration) make the recommendation removal rather than generalization:
1. The biochemically exact term GO:0001512 "dihydronicotinamide riboside quinone reductase activity" (NRH + quinone → nicotinamide riboside + hydroquinone) is already annotated to NQO2 with experimental evidence — IDA, PMID:18254726 (plus IEA GO_REF:0000120).
2. GO:0003955 is NOT an is_a ancestor of GO:0001512. They are siblings in different oxidoreductase subtrees, so GO:0003955 cannot be defended as a merely-less-specific but still-true parent. It is a distinct, incorrect molecular function.
The IBA is therefore a paralog over-annotation (GO:0003955 native to NQO1, propagated across the shared PANTHER family via GO_REF:0000033), and it is both wrong on substrate and redundant with the correct experimental term.
Most important caveat: Do not delete NQO2's reductase function from the model — it is captured accurately by GO:0001512. The action is limited to the mis-specified IBA row.
Evidence Matrix
| Citation |
Evidence type |
Stance |
Claim tested |
Key finding |
Context |
Confidence / limitations |
| PMID:9367528 (Wu et al., 1997) |
Direct assay (purified enzyme) |
Refutes cofactor |
Does NQO2 use NAD(P)H? |
"NQO2 uses dihydronicotinamide riboside (NRH) rather than NAD(P)H as an electron donor"; FAD dimer; 2-e⁻ quinone reduction; dicoumarol-resistant |
Recombinant human NQO2 |
High; definitive; in vitro |
| PMID:18254726 (Calamini et al., 2008) |
Direct assay + X-ray structure |
Supports correct term |
NQO2 activity/structure & ligands |
Kinetic/thermodynamic/X-ray characterization of QR2; source of NQO2 IDA GO:0001512, FAD binding, Zn²⁺ binding, melatonin binding |
Human QR2 crystal |
High |
| PMID:10945627 (Knox et al., 2000; context ref) |
Direct assay |
Qualifies (co-substrate) |
NQO2 oxidoreductase mechanism |
CB1954 bioactivation by NQO2 is co-substrate (NRH-analog)-mediated; IDA source for GO:0016491/0016661/0009055 |
Human NQO2 |
High; confirms NRH-type co-substrate, not NAD(P)H |
| UniProt P16083 (curated) |
Database |
Qualifies |
Correct EC & reaction |
EC 1.10.5.1; reaction NRH + quinone → nicotinamide riboside + quinol; cofactors FAD, Zn²⁺; 231 aa |
Human |
High |
| UniProt P15559 (NQO1) |
Database (paralog) |
Competing/explanatory |
Which enzyme owns GO:0003955? |
NQO1 = EC 1.6.5.2, NADH/NADPH reactions, 274 aa |
Human |
High; source of IBA carry-over |
| QuickGO ontology (this run) |
Computational (ontology) |
Qualifies |
Is GO:0003955 a valid parent of the true term? |
GO:0001512 is_a ancestors = GO:0016679→GO:0016491; GO:0003955 not an ancestor (sibling, not parent) |
GO release |
High; direct API result |
| QuickGO annotation (this run) |
Database |
Supports removal |
Is the correct term already present? |
NQO2 already has GO:0001512 (IDA, PMID:18254726; IEA); GO:0003955 present only as IBA (GO_REF:0000033) |
UniProtKB:P16083 |
High |
| PMID:18996184 (Gaikwad et al., 2009) |
Direct assay |
Supports reductase core |
Does NQO2 reduce quinones? |
NQO2 reduces estrogen o-quinones using an NRH-type cofactor (BNAH); faster than NQO1 |
Human recombinant |
Med-high |
| PMID:21506232 (Dufour et al., 2011) |
Structural/inhibitor |
Qualifies (flavoprotein) |
Mechanism & FAD |
FAD flavoprotein; inhibitors alkylate flavin; NQO1-distinct selectivity |
X-ray + MS |
High |
GO Curation Implications
Lead (requires curator verification):
- Molecular Function — REMOVE the IBA GO:0003955 from NQO2 (or mark NOT / do-not-propagate). It asserts NAD(P)H substrate that NQO2 cannot use and is a paralog carry-over from NQO1.
- Retain the already-present GO:0001512 "dihydronicotinamide riboside quinone reductase activity" (IDA, PMID:18254726) as the accurate leaf MF term. No new term needs to be created.
- Because GO:0003955 is a sibling (not ancestor) of GO:0001512, keeping it is not a harmless generalization — it introduces a false substrate assertion into the model.
- Broader true ancestors already annotated (GO:0016491 oxidoreductase activity; GO:0016661 acting on other nitrogenous donors; GO:0009055 electron transfer activity; GO:0048038 quinone binding; GO:0071949 FAD binding; GO:0008270 zinc ion binding) remain valid. Avoid defaulting to generic "protein binding."
GO decision table
| Term |
Current on NQO2 |
Recommended action |
Basis |
| GO:0003955 NAD(P)H dehydrogenase (quinone) activity |
IBA (GO_REF:0000033) |
Remove / NOT — substrate-incorrect, paralog carry-over, non-ancestral to true term |
PMID:9367528; UniProt EC 1.10.5.1; QuickGO ancestry |
| GO:0001512 dihydronicotinamide riboside quinone reductase activity |
IDA (PMID:18254726) + IEA |
Retain as accurate MF leaf term |
PMID:9367528, 18254726; EC 1.10.5.1 |
{{figure:NQO2_GO_decision_table.png|caption=GO molecular-function decision table for NQO2 (P16083). GO:0003955 "NAD(P)H dehydrogenase (quinone) activity" (IBA, GO_REF:0000033) is substrate-incorrect (NQO2 uses NRH, not NAD(P)H; PMID:9367528) and redundant with the already-annotated, experimentally-supported GO:0001512 "dihydronicotinamide riboside quinone reductase activity" (IDA, PMID:18254726). Recommended action: remove GO:0003955; retain GO:0001512.}}
Mechanistic Scope
- Immediate molecular function tested: FAD-mediated two-electron reduction of quinones to hydroquinones, electrons supplied by a dihydronicotinamide riboside (NRH) donor in a ping-pong mechanism; Zn²⁺ is structural.
- Correctly in scope: quinone reduction (menadione and other quinones, estrogen o-quinones, vitamin K quinones), NRH-dependent nitroreduction (CB1954). Captured by GO:0001512.
- Out of scope for this MF term (BP/CC or ligand-binding): neuronal "memory constraint"/metabolic-buffer role (Rosenblum lab), Alzheimer's phenotype modulation, melatonin MT3 binding-site identity (GO:1904408) and resveratrol binding (GO:1905594). These are downstream physiology or ligand properties, not the electron-donor chemistry adjudicated here.
Conflicts and Alternatives
- Paralog confusion (primary): GO:0003955 is correct for NQO1 (EC 1.6.5.2, NADH/NADPH). Its presence on NQO2 is explained by IBA propagation, not NQO2 biochemistry. Structural basis: NQO2 (231 aa) lacks the ~43-residue C-terminal region present in NQO1 (274 aa) that helps form the adenosine/2′-phosphate NAD(P)H-binding site, so NQO2 uses the smaller NRH.
- In-vitro cofactor surrogates: NQO2 assays use synthetic donors (BNAH; EP-0152R) because free NRH is not a standard bulk metabolite; consistent with EC 1.10.5.1, not with NAD(P)H use.
- No credible primary report shows efficient NAD(P)H-driven catalysis by NQO2.
- Self-correction: Iteration 1 tentatively named the replacement term GO:0033856; that ID is actually pyridoxine 5′-phosphate synthase activity. The correct term is GO:0001512, confirmed via QuickGO.
Knowledge Gaps
- Physiological NRH source in vivo. Checked: literature uses in-vitro NRH/BNAH surrogates. Matters for BP context, not the MF term. Resolve via tissue metabolomics for NRH and NRH-generating enzymes.
- Whether the review pipeline treats a non-ancestral IBA as "generalize" vs "remove." Checked ancestry (GO:0003955 not ancestor of GO:0001512), which argues for removal. Curator should confirm project policy.
- Quantitative NAD(P)H vs NRH kinetics. Existing data are qualitative (NRH-preference). A kcat/Km ratio would formally bound the error; confirmatory only.
Discriminating Tests
- Side-by-side kinetics: NQO2 quinone reduction with NRH/BNAH vs NADH vs NADPH → expect robust NRH activity, negligible NAD(P)H (discriminates GO:0001512 from GO:0003955).
- Structure/domain check: confirm absence of the NQO1 C-terminal NAD(P)H subdomain in NQO2 (PDB 1QR2 vs NQO1 structures; sequence alignment).
- Chimera/mutagenesis: graft the NQO1 C-terminal extension onto NQO2 to test gain of NAD(P)H use — causal test of the domain–cofactor link.
Curation Leads (require curator verification)
- Candidate action: Remove/NOT the IBA GO:0003955 on NQO2; retain existing IDA GO:0001512.
- Candidate reference to verify (donor specificity): PMID:9367528 — "NQO2 uses dihydronicotinamide riboside (NRH) rather than NAD(P)H as an electron donor. It catalyzes a two-electron reduction of quinones and oxidation-reduction dyes."
- Candidate reference supporting the correct term (already the IDA source): PMID:18254726 (Calamini et al., 2008, QR2 kinetics + X-ray) — verify it is the IDA basis for GO:0001512.
- Context reference: PMID:10945627 (CB1954 co-substrate-mediated bioactivation) confirms NRH-type co-substrate, not NAD(P)H.
- Database support: UniProt P16083 (EC 1.10.5.1, NRH→quinol reaction, FAD+Zn²⁺); QuickGO ancestry showing GO:0003955 is not an ancestor of GO:0001512.
- Suggested curator question: Does project policy remove a substrate-incorrect, non-ancestral IBA term when the correct experimental term is already present, or retain it flagged?
- Suggested experiment: NRH-vs-NAD(P)H kinetic comparison to document cofactor discrimination quantitatively.
Provenance (executed this review)
- UniProt REST: NQO2 P16083 = 231 aa, EC 1.10.5.1, NRH→quinol, FAD+Zn²⁺; NQO1 P15559 = 274 aa, EC 1.6.5.2, NAD(H)/NADP(H). Confirms paralog cofactor divergence + 43-aa length difference.
- QuickGO ontology: GO:0001512 is_a ancestors = {GO:0016679, GO:0016491, GO:0003824, GO:0003674}; GO:0003955 NOT among them (sibling relationship).
- QuickGO annotation (UniProtKB:P16083, MF): GO:0001512 = IDA (PMID:18254726) + IEA; GO:0003955 = IBA only (GO_REF:0000033).
- NCBI eSummary: PMID:18254726 = QR2 melatonin kinetics/X-ray; PMID:10945627 = CB1954 co-substrate bioactivation.
- Sequence comparison (UniProt FASTA, computed): NQO2 231 aa vs NQO1 274 aa; NQO1 carries exactly 43 extra C-terminal residues (…NFQAGFLMKKEVQDEEKNKKFGLSVGHHLGKSIPTDNQIKARK) absent in NQO2 — the C-terminal segment forming part of the NAD(P)H adenosine-binding site, i.e. the structural reason NQO2 cannot use NAD(P)H.
- Literature: PMID:9367528 (definitive), 18996184, 21506232, plus review 18374191.
Artifacts generated
NQO2_GO_decision_table.png — rendered GO MF decision table (remove IBA GO:0003955; retain GO:0001512), auto-saved during execution.
- Evidence matrix and GO decision table are embedded above as artifact-friendly Markdown tables (the code executor sandbox could not write CSVs to the job directory; the executed code and its printed outputs above are the provenance).
Artifacts